183232-62-4

Basic information

• Product Name: 5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYLPYRAZOLE-3-CARBOXYLICACID
• Synonyms: 1-(2,4-Dichlorophenyl)-4-methyl-5-(4-bromophenyl)-1H-pyrazole-3-carboxylicacid ethyl ester;5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acidethyl ester; Ethyl5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylate
• CAS NO: 183232-62-4
• Molecular Formula: C₁₉H₁₅BrCl₂N₂O₂
• Molecular Weight: 381.64
• Mol File: 183232-62-4.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYLPYRAZOLE-3-CARBOXYLICACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYLPYRAZOLE-3-CARBOXYLICACID(183232-62-4)
• EPA Substance Registry System: 5-(4-CHLOROPHENYL)-1-(2,4-DICHLOROPHENYL)-4-METHYLPYRAZOLE-3-CARBOXYLICACID(183232-62-4)

Safety Data

• Hazardous Substances Data: 183232-62-4(Hazardous Substances Data)

Upstream product

• 13123-92-7 (2,4-dichlorophenyl)hydrazine 
• 850554-39-1 ethyl 2,4-dioxo-3-methyl-4-(4-bromophenyl)butanoate lithium salt 
• 5446-18-4 2,4-dichlorophenyl hydrazine hydrochloride 
• 5467-74-3 4-Bromophenylboronic acid 
• 64-17-5 ethanol 
• 1166390-93-7 ethyl 4-(4-bromophenyl)-3-methyl-2,4-dioxobutanoate 
• 10342-83-3 4'-Bromopropiophenone 
• 95-92-1 oxalic acid diethyl ester 
• 288104-75-6 4-(4-bromo-phenyl)-2-[(2,4-dichloro-phenyl)-hydrazono]-3-methyl-4-oxo-butyric acid ethyl ester 

Downstream Products

• 1245626-05-4 AM 6545 
• 288104-76-7 ethyl 4-(bromomethyl)-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylate 
• 183232-66-8 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide 
• 183232-63-5 1-(2,4-dichlorophenyl)-5-(4-bromophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide 
• 183232-64-6 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic chloride 
• 850554-41-5 1-(2,4-dichloro-phenyl)-4-methyl-5-{4-[5-(tetrahydro-pyran-2-yloxy)-pentyl]-phenyl}-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide 
• 850554-43-7 methanesulfonic acid 5-{4-[2-(2,4-dichloro-phenyl)-4-methyl-5-(piperidin-1-ylcarbamoyl)-2H-pyrazol-3-yl]-phenyl}-pentyl ester 
• 850554-42-6 N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-{4-(5-hydroxypentyl)phenyl}-4-methyl-1H-pyrazole-3-carboxamide 

Relevant articles and documents

Process for Making Biologically Active Compounds and Intermediates Thereof

A process of manufacturing biologically active compounds, their analogs, pharmaceutically acceptable salts, solvates, polymorphs, isotopic variants, and intermediates thereof. Notably, the compounds of the formula IA, 1B, 1C. 1D. 1E, 1F and IG for which novel processes have been disclosed, selectively act on the cannabinoid receptors, and with high affinity. The processes for the preparation of the compounds enable the syntheses of cannabinoid modulators on a large-scale that are eco-friendly and economically viable. Additionally, the processes disclosed enable the synthesis of cannabinoid modulators with high purity and in high yield for their use in making drug substance and drug products.

Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB1R molecular probes

The cannabinoid-1 receptor (CB1R) inverse agonist SR141716A has proven useful for study of the endocannabinoid system, including development of divalent CB1R ligands possessing a second functional motif attached via a linker unit. These have predominantly employed the C3 position of the central pyrazole ring for linker attachment. Despite this precedent, a novel series of C3-linked CB1R-D2R divalent ligands exhibited extremely high affinity at the D2R, but only poor affinity for the CB1R. A systematic linker attachment point survey of the SR141716A pharmacophore was therefore undertaken, establishing the C5 position as the optimal site for linker conjugation. This linker attachment survey enabled the identification of a novel divalent ligand as a lead compound to inform ongoing development of high-affinity CB1R molecular probes.

Imidazol-4-one and Imidazole-4-thione Compounds

Imidazol-4-one or imidazole-4-thione compounds of formula (I): wherein X, R1, R2, R3, R4, R5, and R6 are defined herein. Also disclosed is a method for treating a cannabinoid receptor-mediated disorder with these compounds.